MA37700B1 - N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments - Google Patents

N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments

Info

Publication number
MA37700B1
MA37700B1 MA37700A MA37700A MA37700B1 MA 37700 B1 MA37700 B1 MA 37700B1 MA 37700 A MA37700 A MA 37700A MA 37700 A MA37700 A MA 37700A MA 37700 B1 MA37700 B1 MA 37700B1
Authority
MA
Morocco
Prior art keywords
arylcarboxamides
quinolin
yloxy
hetero
cyclohexyl
Prior art date
Application number
MA37700A
Other languages
English (en)
Other versions
MA20150269A1 (fr
Inventor
Hermann Künzer
Benjamin Bader
Duy Nguyen
Silke Köhr
Martin Fritsch
Gimenez Hortensia Faus
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37700(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA20150269A1 publication Critical patent/MA20150269A1/fr
Publication of MA37700B1 publication Critical patent/MA37700B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne les n-[4-(quinolin-4-yloxy)cyclohexyl (méthyl)](hétéro)arylcarboxamides, leurs intermédiaires et leurs procédés de production, leur utilisation pour traiter et/ou prévenir des maladies et leur utilisation en vue de la production de médicaments, ainsi que l'utilisation de ces derniers en vue du traitement et/ou de la prévention de maladies, dont, plus particulièrement, les maladies hyperprolifératives.
MA37700A 2012-06-26 2013-06-24 N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments MA37700B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12004764 2012-06-26
PCT/EP2013/063118 WO2014001247A1 (fr) 2012-06-26 2013-06-24 N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments

Publications (2)

Publication Number Publication Date
MA20150269A1 MA20150269A1 (fr) 2015-08-31
MA37700B1 true MA37700B1 (fr) 2018-03-30

Family

ID=48699019

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37700A MA37700B1 (fr) 2012-06-26 2013-06-24 N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments

Country Status (41)

Country Link
US (1) US9428460B2 (fr)
EP (1) EP2864291B1 (fr)
JP (1) JP6181172B2 (fr)
KR (1) KR20150023880A (fr)
AP (1) AP3919A (fr)
AR (1) AR091565A1 (fr)
AU (1) AU2013283543B2 (fr)
BR (1) BR112014032538A2 (fr)
CA (1) CA2877786C (fr)
CL (1) CL2014003443A1 (fr)
CO (1) CO7170167A2 (fr)
CR (1) CR20140593A (fr)
CU (1) CU20140144A7 (fr)
CY (1) CY1118412T1 (fr)
DK (1) DK2864291T3 (fr)
DO (1) DOP2014000295A (fr)
EA (1) EA028063B1 (fr)
EC (1) ECSP14032516A (fr)
ES (1) ES2609455T3 (fr)
HK (1) HK1206346A1 (fr)
HR (1) HRP20161745T1 (fr)
HU (1) HUE032306T2 (fr)
IL (1) IL236146B (fr)
JO (1) JO3342B1 (fr)
LT (1) LT2864291T (fr)
MA (1) MA37700B1 (fr)
ME (1) ME02590B (fr)
MX (1) MX2014016054A (fr)
NZ (1) NZ703100A (fr)
PE (1) PE20150154A1 (fr)
PH (1) PH12014502869B1 (fr)
PL (1) PL2864291T3 (fr)
PT (1) PT2864291T (fr)
RS (1) RS55500B1 (fr)
SG (1) SG11201408254UA (fr)
SI (1) SI2864291T1 (fr)
TN (1) TN2014000532A1 (fr)
TW (1) TWI600646B (fr)
UA (1) UA115447C2 (fr)
UY (1) UY34881A (fr)
WO (1) WO2014001247A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3134091A4 (fr) * 2014-04-22 2017-08-30 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisation
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10544099B2 (en) 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109311816A (zh) 2016-05-04 2019-02-05 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328821A (en) 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU2001268040A1 (en) 2000-06-23 2002-01-08 Eli Lilly And Company Methods and compounds for inhibiting mrp1
CN100415720C (zh) 2001-06-22 2008-09-03 麒麟医药株式会社 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
US7176227B2 (en) 2002-09-11 2007-02-13 Kureha Corporation Amine compounds and use thereof
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
WO2004067516A1 (fr) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de 2,4-diaminopyrimidine utiles en tant qu'inhibiteurs de l'enzyme pkc-theta
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
JP2007529511A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
WO2005117570A1 (fr) 2004-05-27 2005-12-15 Jack Saffron Coupelle pour aliments empechant l'infestation par des parasites
KR20070086044A (ko) 2004-11-09 2007-08-27 스미스클라인 비참 코포레이션 글리코겐 포스포릴라제 억제제 화합물 및 이의 약제학적조성물
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
US20060293341A1 (en) 2005-06-23 2006-12-28 Vrej Jubian Alkyl sulfonamide derivatives
WO2007091694A1 (fr) 2006-02-06 2007-08-16 Showa Denko K.K. Préparations dermatologiques de blanchiment
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008064432A1 (fr) 2006-12-01 2008-06-05 The University Of Sydney Composés moléculaires polycycliques
US8377949B2 (en) 2007-08-16 2013-02-19 Boehringer Ingelheim International Gmbh Quinazolinedione chymase inhibitors
CA2966280A1 (fr) * 2007-10-26 2009-04-30 The Regents Of The University Of California Composes de diaryl-hydantoine
EP2288383A1 (fr) 2008-05-14 2011-03-02 Amgen, Inc Combinaisons d'inhibiteurs de vegf(r) et d'inhibiteurs du facteur de croissance d'hépatocyte (c-met) pour le traitement du cancer
CA2738583A1 (fr) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methodes de traitement du cancer
AR077765A1 (es) 2009-07-21 2011-09-21 Gilead Sciences Inc Inhibidores de los virus flaviviridae
EP2475366A1 (fr) 2009-09-11 2012-07-18 Bayer Pharma Aktiengesellschaft Thiohydantoïnes à substitution hétéroarylméthyle, en tant que médicaments anticancer
PT2592933T (pt) 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações

Also Published As

Publication number Publication date
PL2864291T3 (pl) 2017-07-31
LT2864291T (lt) 2017-01-10
JO3342B1 (ar) 2019-03-13
BR112014032538A2 (pt) 2017-06-27
NZ703100A (en) 2016-10-28
CY1118412T1 (el) 2017-06-28
US9428460B2 (en) 2016-08-30
CR20140593A (es) 2015-02-16
CN104684896A (zh) 2015-06-03
HRP20161745T1 (hr) 2017-02-24
PE20150154A1 (es) 2015-02-19
JP2015521641A (ja) 2015-07-30
HK1206346A1 (en) 2016-01-08
EA201500039A1 (ru) 2015-06-30
TW201400460A (zh) 2014-01-01
US20150191431A1 (en) 2015-07-09
AR091565A1 (es) 2015-02-11
PT2864291T (pt) 2017-01-06
CU20140144A7 (es) 2015-08-27
CA2877786A1 (fr) 2014-01-03
TN2014000532A1 (en) 2016-03-30
AP2014008141A0 (en) 2014-12-31
PH12014502869A1 (en) 2015-02-23
SI2864291T1 (sl) 2017-01-31
CO7170167A2 (es) 2015-01-28
TWI600646B (zh) 2017-10-01
RS55500B1 (sr) 2017-05-31
IL236146A0 (en) 2015-02-01
ME02590B (fr) 2017-06-20
UY34881A (es) 2014-01-31
ES2609455T3 (es) 2017-04-20
JP6181172B2 (ja) 2017-08-16
HUE032306T2 (en) 2017-09-28
AP3919A (en) 2016-11-30
AU2013283543A1 (en) 2015-01-29
SG11201408254UA (en) 2015-01-29
AU2013283543B2 (en) 2017-11-02
EP2864291B1 (fr) 2016-10-05
MX2014016054A (es) 2015-04-10
CL2014003443A1 (es) 2015-06-26
KR20150023880A (ko) 2015-03-05
EP2864291A1 (fr) 2015-04-29
EA028063B1 (ru) 2017-10-31
CA2877786C (fr) 2020-08-25
DK2864291T3 (en) 2017-01-16
DOP2014000295A (es) 2015-01-31
MA20150269A1 (fr) 2015-08-31
WO2014001247A1 (fr) 2014-01-03
ECSP14032516A (es) 2015-12-31
PH12014502869B1 (en) 2015-02-23
UA115447C2 (uk) 2017-11-10
IL236146B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA42376A (fr) Dérivés d'oxopyridine substitués
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA35844B1 (fr) Pyrimidines et triazines annelées substituées et leur utilisation
EA201500362A1 (ru) Ингибиторы rho-киназы
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA33987B1 (fr) Bloqueurs de canaux sodiques sensibles au potentiel
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
BR112013008140A8 (pt) "compostos imidazotriazinona".
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
FR3012725B1 (fr) Compositions d'agents de lutte biologique, leur procede de preparation et leurs utilisations
MA37700B1 (fr) N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA38925B1 (fr) Dérivés de phénylalanine substitués
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
MA33290B1 (fr) Pipéridines substituées
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MX2014014066A (es) Compuestos de cromano.
MA33291B1 (fr) Pipéridines substituées
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
PH12015500322A1 (en) Tris(hetero)arylpyrazoles and use thereof
MA39118B1 (fr) Quinazoline-thf-amines utilisées en tant qu'inhibiteurs de la pde1
MA35894B1 (fr) Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k
MA38636A1 (fr) Composés de 3,4-dihydroisoquinoléin-2(1h)-yle